Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With
ALK-Positive Non–Small-Cell Lung Cancer - PMC Back to Top Skip to main content NIH NLM …

Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

Background The ALEX study demonstrated significantly improved progression-free survival
(PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung …

Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic
lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase …

Background Mature progression-free survival (PFS) data from the phase III J-ALEX study
showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …

Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …